<DOC>
	<DOCNO>NCT02191059</DOCNO>
	<brief_summary>1 . There yet optimal treatment regimen patient epidermal growth factor receptor ( EGFR ) gene wild type non-small-cell lung cancer ( NSCLC ) . 2 . Icotinib new type small molecule EGFR TKI , develop patent Zhejiang BetaPharma Co. , Ltd. ( Hangzhou , Zhejiang , China , Patent No . WO2003082830 ) . It similar anti-tumor activity gefitinib , erlotinib . Pre-clinical study show icotinib could significantly inhibit EGFR tyrosine kinase activity . Notably , anti-tumor activity observe patient advanced NSCLC . 3 . In study , evaluate efficiency intermittent high dose Icotinib combination Docetaxel second-line treatment NSCLC patient wild type EGFR . The overall response rate ( ORR ) , progression free survival ( PFS ) , overall survival ( OS ) health relate quality life ( HRQoL ) monitor .</brief_summary>
	<brief_title>Phase II Clinical Study Intermittent High Dose Icotinib Combination With Docetaxel Treat Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm stage IIIB/IV NSCLC patient progress firstline chemotherapy ; Patients must stop prior platinumbased therapy least four week prior enroll fully recover chemotherapyinduced toxicity ; Age : 1870 year old ; Patients wildtype EGFR ; With histologically cytologically confirm measurable disease ( long diameter &gt; =10mm Spiral compute tomography ( CT ) &gt; =20mm conventional CT ) accord Response Evaluation Criteria Solid Tumors ( RECIST Criteria ) ; Patients must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 ; Must expect survival time least 12 week ; Patients adequate bone marrow function define absolute peripheral neutrophil count ( ANC ) ≥1.5 ´ 109/L , platelet count ≥ 75´ 109/L ; Hemoglobin ( Hb ) ≥ 9g/dL ; adequate hepatic function : bilirubin ≤2x upper limit normal , glutamicoxaloacetic transaminase ( AST ) glutamate pyruvate transaminase ( ALT ) ≤2x upper limit normal ( ≤5x upper limit normal evidence liver metastasis ) ; adequate renal function : bilirubin serum creatinine ≤1.5 x upper limit normal ; No malabsorption gastrointestinal disorder affect drug absorption ; Female patient childbearing potential must negative serum urine pregnancy test within 7 day prior study entry.Male patient must use least one reliable form contraception treatment within 3 month treatment ; Patients provide sign Informed Consent Form . Experience AntiEGFR Monoclonal Antibody small molecular compound therapy gefitinib , cetuximab , erlotinib trastuzumab ; Concomitant use phenytoin , carbamazepine , rifampicin , phenobarbital St. John 's Wort ; Allergic icotinib excipients product . Prior chemotherapy paclitaxel agent ; Central nervous system ( CNS ) metastases without radiotherapy and/or surgery ; Evidence clinically active Interstitial lung disease ; Severe systemic disease control unstable uncompensated respiratory , cardiac , liver , renal disease ; Patient concurrent malignancy malignancy within 5 year study enrollment , ( exception non melanoma skin cancer cervical carcinoma situ ) ; Psychiatric illness would prevent patient give informed consent ; Evidence significant clinical disorder laboratory find make undesirable subject participate study ; Patient concurrently use approve investigational antineoplastic agent ; Pregnant lactate woman ; Positive epidermal growth factor receptor mutation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Wild Type EGFR</keyword>
	<keyword>Icotinib</keyword>
	<keyword>Second-line Treatment</keyword>
</DOC>